AI Tool Studied to Support Pulmonary Tuberculosis Care Decisions
Studies an artificial intelligence support tool for people with lung tuberculosis.
Plain-language title generated from the registry record
Registry title: Artificial Intelligence-driven Tuberculosis Landscape Analysis & Stratification Research
Key facts
- Where
- Changsha and Shanghai, ChinaSee the 2 sites
Where in China
- Hunan Chest HospitalChangsha, ChinaNo longer taking part
- Huashan Hospital Affiliated to Fudan UniversityShanghai, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Huashan Hospital
- Trial code
- NCT07611695
- Record updated
- 28 May 2026
- Original description
The goal of this observational study is to establish and validate a comprehensive AI-driven clinical decision support system (AI-CDSS) in whole-chain management for pulmonary tuberculosis (TB) patients. The main question it aims to answer is:Read full original descriptionShow less
Artificial Intelligence-driven Tuberculosis Landscape Analysis & Stratification Research
The goal of this observational study is to establish and validate a comprehensive AI-driven clinical decision support system (AI-CDSS) in whole-chain management for pulmonary tuberculosis (TB) patients. The main question it aims to answer is:
How is the predictive performance of this system in terms of multiple key links during TB diagnosis and treatment? Can real-world benefits be derived from this system? This AI framework supports clinicians in making smarter decisions, ultimately improving cure rates and ensuring that every patient receives the most effective, personalized care possible.
Inclusion: Patient with clinically diagnosed or bacteriologically confirmed pulmonary tuberculosis (TB) who received TB treatment; Initiation of TB treatment on or after January 1, 2021; Complete key diagnosis and treatment data available in the electronic medical record system; Patient with clinically diagnosed or bacteriologically confirmed pulmonary tuberculosis (TB) who is planning to start TB treatment; Voluntary participation with signed informed consent form (for adults ≥18 years); parental / guardian consent and co-signed informed consent form are required for minors aged ≤ 18 years.
Exclusion: Co-morbidity confounding: the presence of other active, life-threatening disease (e.g. late-stage malignancy, non-HIV severe immunodeficiency) for which the expected survival or priority of treatment may substantially interfere with the attribution of TB treatment outcomes; Extremely poor treatment adherence: documented evidence indicating that the patient either never initiated treatment or was permanently lost to follow-up within the early treatment period (<2 weeks), precluding the collection of any valid outcome data.